Prothena to Participate in BIO CEO & Investor and Leerink Partners Healthcare Conferences

DUBLIN, Ireland, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in two upcoming meetings:

• BIO CEO & Investor Conference on February 8, 2016 in New York, NY. Prothena President and Chief Executive Officer Dale B. Schenk, PhD will present an update on the company's business at 10:00 AM ET and participate in a fireside chat at 1:30 PM ET.
   
• Leerink Partners 5th Annual Global Healthcare Conference on February 11, 2016 at 8:55 AM ET in New York, NY.

A live webcast of the presentations from both conferences can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, replays of the webcasts will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company is developing antibody-based product candidates that target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and psoriasis and other inflammatory diseases (PRX003).

For more information, please visit the company's web site at www.prothena.com.

Contacts

Investors: Tran Nguyen, CFO
650-837-8535, IR@prothena.com

Media: Ellen Rose
650-922-2405, ellen.rose@prothena.com